Novartis /
Tourmaline Bio, Inc.
Novartis completes Tourmaline Bio acquisition
Source for the buyer and target: Novartis AG
For the buyer and target.
“Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”).”
Published 28 Oct 2025
Open the sourceWhat happened
Novartis completed its acquisition of Tourmaline Bio, Inc. The transaction was conducted through a tender offer followed by a merger. [01]
The tender offer was priced at $48.00 per share in cash. Tourmaline Bio is now an indirect wholly owned subsidiary of Novartis. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Novartis completes Tourmaline Bio acquisition
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly